ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Autologous Tumor Infiltrating Lymphocytes LN-145

Also written as “LN-145”, “Autologous Tumor Infiltrating Lymphocytes” and “LN-145/LN-144”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Sarcoma · Uterine Cervical Neoplasms · Melanoma · Squamous Cell Carcinoma of Head and Neck, led by 2 companies.

Drug pageAutologous Tumor Infiltrating Lymphocytes LN-145: every studyAll 15 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Mar 14, 20178 company-led studies, 3 open or runningNext primary completion: Jan 1, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Iovance Biotherapeuticsits history only61 open or runningphase 2since Mar 14, 2017Mar 14, 2017Dec 2030phase 2 · NCT04614103
Shanghai Juncell Therapeuticsits history only22 open or runningphase 2since Apr 24, 2026Jun 18, 2024Jan 1, 2027phase 1 · NCT06473961

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 14, 2017First studies: 2 phase 2 studiesNew to Iovance BiotherapeuticsIovance Biotherapeutics · NCT03083873, NCT03108495
  2. Jan 14, 2018Phase 2 study in Carcinoma, Non-Small-Cell LungIovance Biotherapeutics · NCT03419559 · United States
  3. Aug 22, 2018Phase 2 study in MelanomaIovance Biotherapeutics · NCT03645928 · 225 enrolled · United States, Canada, Germany and more
  4. Oct 21, 2020Phase 2 study in Carcinoma, Non-Small-Cell LungIovance Biotherapeutics · NCT04614103 · 170 planned · United States, Australia, Canada and more
  5. Jun 18, 2024Shanghai Juncell Therapeutics’ first study: phase 1 study in Carcinoma, Non-Small-Cell LungNew to Shanghai Juncell TherapeuticsShanghai Juncell Therapeutics · NCT06473961 · 20 planned · China
  6. Jul 17, 2024Phase 1 study in SarcomaIovance Biotherapeutics · NCT06566092 · 5 enrolled · United States
  7. Apr 24, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungPhase 2 reachedShanghai Juncell Therapeutics · NCT07560111 · 28 planned · China

Ahead

  1. Jan 1, 2027Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungShanghai Juncell Therapeutics · NCT06473961
  2. Jun 1, 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungShanghai Juncell Therapeutics · NCT07560111
  3. Dec 2030Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungIovance Biotherapeutics · NCT04614103

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07560111Carcinoma, Non-Small-Cell Lung · China2RecruitingShanghai Juncell TherapeuticsJun 1, 202728
NCT06566092Sarcoma · United States1TerminatedIovance BiotherapeuticsJun 19, 20265
NCT06473961Carcinoma, Non-Small-Cell Lung · China1RecruitingShanghai Juncell TherapeuticsJan 1, 202720
NCT04614103Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more2RecruitingIovance BiotherapeuticsDec 2030170
NCT03645928Melanoma · United States, Canada, Germany and more2TerminatedIovance BiotherapeuticsFeb 20, 2026225
NCT03419559Carcinoma, Non-Small-Cell Lung · United States2WithdrawnIovance BiotherapeuticsDec 20210
NCT03108495Uterine Cervical Neoplasms · United States, France, Germany and more2TerminatedIovance BiotherapeuticsAug 22, 2025210
NCT03083873Squamous Cell Carcinoma of Head and Neck · United States2CompletedIovance BiotherapeuticsAug 8, 202264

How it is read

Names in the registry

  • “LN-145”, 6 entries
  • “Autologous Tumor Infiltrating Lymphocytes”, 2 entries
  • “LN-145/LN-144”, 1 entry
  • “LN-145 + pembrolizumab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
Autologous Tumor Infiltrating Lymphocytes LN-145: development by 2 companies | ClinicalTrials.gg